NLRP3 and primary cutaneous T-cell non-Hodgkin lymphoma: These results indicate that NLRP3 might be a key regulator of IL-4 expression in TOX+ CD4+ T cells of CTCL patients and that this mechanism might have important implications in the progression of the disease.